Cancer Research Cancer Research Funding Available  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Komatani, H.
Right arrow Articles by Nishimura, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komatani, H.
Right arrow Articles by Nishimura, S.
[Cancer Research 61, 2827-2832, April 1, 2001]
© 2001 American Association for Cancer Research


Advances in Brief

Identification of Breast Cancer Resistant Protein/Mitoxantrone Resistance/Placenta-Specific, ATP-binding Cassette Transporter as a Transporter of NB-506 and J-107088, Topoisomerase I Inhibitors with an Indolocarbazole Structure

Hideya Komatani1, Hidehito Kotani, Yoshikazu Hara, Rinako Nakagawa, Mami Matsumoto, Hiroharu Arakawa and Susumu Nishimura

Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Ibaraki, 300-2611, Japan [H. Kom., H. Kot., Y. H., R. N., H. A., S. N.], and Clinical Development Institute, Banyu Pharmaceutical Co. Ltd., Tokyo 103-0026, Japan [M. M.]

The antitumor drugs NB-506 and J-107088 are potent topoisomerase I inhibitors with an indolocarbazole structure. To clarify the factors involved in resistance to these drugs, we established two NB-506-resistant mouse fibroblast cell lines (LY/NR1and LY/NR2), a human colon carcinoma cell line (HCT116/NR1), and a lung cancer cell line (PC13/NR1). These cell lines were highly resistant to NB-506 and J-107088, and LY/NR2 cells showed markedly reduced accumulation and strong efflux of NB-506, suggesting activation of a drug efflux pump in the resistant cells. To identify the molecules responsible for efflux of NB-506, we compared the gene expressions of the mouse resistant LY/NR1 cells, LY/NR2 cells, and their parental cells by oligonucleotide microarray. Of 34,020 genes analyzed, we found that an ATP-binding cassette transporter BCRP/MXR/ABCP (BCRP) gene showed the highest increase in the expression, 31-fold higher in the LY/NR2-resistant cells than in their parental cells. The selective overexpression of this gene was also detected in the two human resistant cell lines, suggesting the involvement of breast cancer resistant protein (BCRP) in the resistance and efflux of these drugs. Finally, a PC-13 cell line transfected with BCRP expression vector displayed 22- and 17-fold resistance to NB-506 and J-107088 and enhanced efflux activity of J-107088. However, the transfectants were not resistant to mitoxantrone or topotecan, the drugs previously thought to be the substrates of BCRP. Thus, our study presents a novel mechanism of drug resistance mediated by BCRP.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
R. W. Robey, S. Shukla, K. Steadman, T. Obrzut, E. M. Finley, S. V. Ambudkar, and S. E. Bates
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
Mol. Cancer Ther., June 1, 2007; 6(6): 1877 - 1885.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Swiatecka-Urban, A. Brown, S. Moreau-Marquis, J. Renuka, B. Coutermarsh, R. Barnaby, K. H. Karlson, T. R. Flotte, M. Fukuda, G. M. Langford, et al.
The Short Apical Membrane Half-life of Rescued {Delta}F508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Results from Accelerated Endocytosis of {Delta}F508-CFTR in Polarized Human Airway Epithelial Cells
J. Biol. Chem., November 4, 2005; 280(44): 36762 - 36772.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Z. Benderra, A. M. Faussat, L. Sayada, J.-Y. Perrot, R. Tang, D. Chaoui, H. Morjani, C. Marzac, J.-P. Marie, and O. Legrand
MRP3, BCRP, and P-Glycoprotein Activities are Prognostic Factors in Adult Acute Myeloid Leukemia
Clin. Cancer Res., November 1, 2005; 11(21): 7764 - 7772.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
B. Ebert, A. Seidel, and A. Lampen
Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists
Carcinogenesis, October 1, 2005; 26(10): 1754 - 1763.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry, and S. E. Bates
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Cancer Res., February 15, 2004; 64(4): 1242 - 1246.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. Nakanishi, L. A. Doyle, B. Hassel, Y. Wei, K. S. Bauer, S. Wu, D. W. Pumplin, H.-B. Fang, and D. D. Ross
Functional Characterization of Human Breast Cancer Resistance Protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis
Mol. Pharmacol., December 1, 2003; 64(6): 1452 - 1462.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Wierdl, A. Wall, C. L. Morton, J. Sampath, M. K. Danks, J. D. Schuetz, and P. M. Potter
Carboxylesterase-Mediated Sensitization of Human Tumor Cells to CPT-11 Cannot Override ABCG2-Mediated Drug Resistance
Mol. Pharmacol., August 1, 2003; 64(2): 279 - 288.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Nakanishi, J. E. Karp, M. Tan, L. A. Doyle, T. Peters, W. Yang, D. Wei, and D. D. Ross
Quantitative Analysis of Breast Cancer Resistance Protein and Cellular Resistance to Flavopiridol in Acute Leukemia Patients
Clin. Cancer Res., August 1, 2003; 9(9): 3320 - 3328.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Shimano, M. Satake, A. Okaya, J. Kitanaka, N. Kitanaka, M. Takemura, M. Sakagami, N. Terada, and T. Tsujimura
Hepatic Oval Cells Have the Side Population Phenotype Defined by Expression of ATP-Binding Cassette Transporter ABCG2/BCRP1
Am. J. Pathol., July 1, 2003; 163(1): 3 - 9.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Allen, S. C. van Dort, M. Buitelaar, O. van Tellingen, and A. H. Schinkel
Mouse Breast Cancer Resistance Protein (Bcrp1/Abcg2) Mediates Etoposide Resistance and Transport, but Etoposide Oral Availability Is Limited Primarily by P-glycoprotein
Cancer Res., March 15, 2003; 63(6): 1339 - 1344.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Ozvegy, A. Varadi, and B. Sarkadi
Characterization of Drug Transport, ATP Hydrolysis, and Nucleotide Trapping by the Human ABCG2 Multidrug Transporter. MODULATION OF SUBSTRATE SPECIFICITY BY A POINT MUTATION
J. Biol. Chem., December 6, 2002; 277(50): 47980 - 47990.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
C. Carrasco, M. Facompre, J. D. Chisholm, D. L. Van Vranken, W. D. Wilson, and C. Bailly
DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer
Nucleic Acids Res., April 15, 2002; 30(8): 1774 - 1781.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. D. Allen, S. C. Jackson, and A. H. Schinkel
A Mutation Hot Spot in the Bcrp1 (Abcg2) Multidrug Transporter in Mouse Cell Lines Selected for Doxorubicin Resistance
Cancer Res., April 1, 2002; 62(8): 2294 - 2299.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. D. Allen and A. H. Schinkel
Multidrug Resistance and Pharmacological Protection Mediated by the Breast Cancer Resistance Protein (BCRP/ABCG2)
Mol. Cancer Ther., April 1, 2002; 1(6): 427 - 434.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.